A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101

Recruiting now

Conditions studied: Refractory Lupus Nephritis, Myasthaenia Gravis, Stiff Person Syndrome, Rheumatoid Arthritis (RA), Multiple Sclerosis, Dermatomyositis, Systemic Sclerosis (SSc)

In brief

The purpose of this long-term follow-up (LTFU) study is to collect delayed adverse events (AEs) and understand the persistence of KYV-101 (autologous CAR T cell product; gene-modified product), in participants who have been administered KYV-101 (gene-modified product; autologous CAR T cell product). This LTFU protocol will be open to any participant who received at least one infusion of KYV-101 in a previous Kyverna sponsored clinical trial or Investigator Initiated Trial (IIT).

Key facts

Study ID

NCT07403188

Run by

Kyverna Therapeutics

People needed

70

Starts

2025-11-24

Expected to finish

2041-01-01

Last updated by the study team

2026-02-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Provided informed consent for the LTFU study
• Received at least 1 infusion of KYV-101 as part of a previous KYV-101 parent treatment protocol

You may not qualify if…

• Not applicable

Where it is running

• University of Colorado, Denver — Denver, Colorado, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.